Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ENANTA PHARMACEUTICALS INCENTA · Entity 5673 | Sr. VP & Chief Medical Officer | April 01, 2022 | April 05, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ENANTA PHARMACEUTICALS INC
Report date April 01, 2022 · Filed April 05, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 34,982 |
Ending reported balance
After 2022-04-04 transaction · row 12
12 source rows · reconciled sequenceRow 1 · 2022-04-01 · Exercise / conversion · Acquired 16,000 · Balance 50,982 Row 2 · 2022-04-01 · Exercise / conversion · Acquired 31,664 · Balance 82,646 Row 3 · 2022-04-01 · Exercise / conversion · Acquired 2,895 · Balance 85,541 Row 4 · 2022-04-01 · Sale · Disposed 8,299 · Balance 77,242 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in December 2021 in contemplation of her previously announced retirement plan. F2: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $70.12 to $71.00, inclusive. Row 5 · 2022-04-01 · Sale · Disposed 42,260 · Balance 34,982 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in December 2021 in contemplation of her previously announced retirement plan. F3: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $71.02 to $72.00, inclusive. Row 6 · 2022-04-04 · Exercise / conversion · Acquired 6,285 · Balance 41,267 Row 7 · 2022-04-04 · Exercise / conversion · Acquired 9,625 · Balance 50,892 Row 8 · 2022-04-04 · Exercise / conversion · Acquired 16,875 · Balance 67,767 Row 9 · 2022-04-04 · Sale · Disposed 2,500 · Balance 65,267 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in December 2021 in contemplation of her previously announced retirement plan. F4: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $70.06 to $70.99, inclusive. Row 10 · 2022-04-04 · Sale · Disposed 18,076 · Balance 47,191 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in December 2021 in contemplation of her previously announced retirement plan. F5: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $71.00 to $71.99, inclusive. Row 11 · 2022-04-04 · Sale · Disposed 3,200 · Balance 43,991 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in December 2021 in contemplation of her previously announced retirement plan. F6: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $72.00 to $72.99, inclusive. Row 12 · 2022-04-04 · Sale · Disposed 9,009 · Balance 34,982 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in December 2021 in contemplation of her previously announced retirement plan. F7: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $73.00 to $73.91, inclusive. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $31.42 · Expires 2025-11-20 | Direct | 0 |
Reported balance
After 2022-04-01 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2022-04-01 · Exercise / conversion · Disposed 16,000 · Balance 0 F8: 100% of the shares subject to the option are fully vested and exercisable. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $30.00 · Expires 2026-11-18 | Direct | 0 |
Reported balance
After 2022-04-01 transaction · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · 2022-04-01 · Exercise / conversion · Disposed 31,664 · Balance 0 F8: 100% of the shares subject to the option are fully vested and exercisable. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $48.52 · Expires 2027-11-17 | Direct | 6,285 |
Reported balance
After 2022-04-01 transaction · row 15
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 15 · 2022-04-01 · Exercise / conversion · Disposed 2,895 · Balance 6,285 F8: 100% of the shares subject to the option are fully vested and exercisable. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $48.52 · Expires 2027-11-17 | Direct | 0 |
Reported balance
After 2022-04-04 transaction · row 16
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 16 · 2022-04-04 · Exercise / conversion · Disposed 6,285 · Balance 0 F8: 100% of the shares subject to the option are fully vested and exercisable. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $43.57 · Expires 2030-11-20 | Direct | 21,175 |
Reported balance
After 2022-04-04 transaction · row 17
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 17 · 2022-04-04 · Exercise / conversion · Disposed 9,625 · Balance 21,175 F9: The option, representing a right to purchase a total of 30,800 shares, became or will become exercisable (subject to the optionholder's continued employment) quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over four years from the date of grant (November 20, 2020). |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $63.35 · Expires 2029-11-18 | Direct | 13,125 |
Reported balance
After 2022-04-04 transaction · row 18
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 18 · 2022-04-04 · Exercise / conversion · Disposed 16,875 · Balance 13,125 F10: The option, representing a right to purchase a total of 30,000 shares, became or will become exercisable (subject to the optionholder's continued employment) quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over four years from the date of grant (November 18, 2019). |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in December 2021 in contemplation of her previously announced retirement plan.
F2: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $70.12 to $71.00, inclusive.
F3: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $71.02 to $72.00, inclusive.
F4: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $70.06 to $70.99, inclusive.
F5: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $71.00 to $71.99, inclusive.
F6: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $72.00 to $72.99, inclusive.
F7: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $73.00 to $73.91, inclusive.
F8: 100% of the shares subject to the option are fully vested and exercisable.
F9: The option, representing a right to purchase a total of 30,800 shares, became or will become exercisable (subject to the optionholder's continued employment) quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over four years from the date of grant (November 20, 2020).
F10: The option, representing a right to purchase a total of 30,000 shares, became or will become exercisable (subject to the optionholder's continued employment) quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over four years from the date of grant (November 18, 2019).
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 01, 2021 Filed Nov 3, 2021 00:33 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | SaleCommon Stock | 1,952 | $84.31 | $164,573.12 |
DisclosureSEC source: 0001177648-21-000029 · edgar.xml · nonDerivative · entry 2 Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,539 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in May 2021. F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $83.74 to $84.73, inclusive. Read SEC document |
| November 01, 2021 Filed Nov 3, 2021 00:33 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | Exercise / conversionCommon Stock | 9,547 | $48.52 | $463,220.44 |
DisclosureSEC source: 0001177648-21-000029 · edgar.xml · nonDerivative · entry 1 Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,491 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 11, 2021 Filed Oct 13, 2021 22:39 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,047 | $0.00 Strike: $43.46 | $0.00 |
DisclosureSEC source: 0001177648-21-000027 · edgar.xml · derivative · entry 6 Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,770 Underlying: Common Stock · 4,047 shares Expires 2025-06-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 100% of the shares subject to the option are fully vested and exercisable. Read SEC document |
| October 11, 2021 Filed Oct 13, 2021 22:39 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | SaleCommon Stock | 4,047 | $70.34 | $284,685.41 |
DisclosureSEC source: 0001177648-21-000027 · edgar.xml · nonDerivative · entry 4 Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,944 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in May 2021. F3 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $70.05 to $70.85, inclusive. Read SEC document |
| October 11, 2021 Filed Oct 13, 2021 22:39 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | Exercise / conversionCommon Stock | 4,047 | $43.46 | $175,882.62 |
DisclosureSEC source: 0001177648-21-000027 · edgar.xml · nonDerivative · entry 3 Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,991 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 08, 2021 Filed Oct 13, 2021 22:39 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | Exercise / conversionStock Option (Right to Buy) · Derivative | 13,453 | $0.00 Strike: $43.46 | $0.00 |
DisclosureSEC source: 0001177648-21-000027 · edgar.xml · derivative · entry 5 Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,817 Underlying: Common Stock · 13,453 shares Expires 2025-06-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 100% of the shares subject to the option are fully vested and exercisable. Read SEC document |
| October 08, 2021 Filed Oct 13, 2021 22:39 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | SaleCommon Stock | 13,453 | $70.09 | $942,934.22 |
DisclosureSEC source: 0001177648-21-000027 · edgar.xml · nonDerivative · entry 2 Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,944 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in May 2021. F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $70.00 to $70.30, inclusive. Read SEC document |
| October 08, 2021 Filed Oct 13, 2021 22:39 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | Exercise / conversionCommon Stock | 13,453 | $43.46 | $584,667.38 |
DisclosureSEC source: 0001177648-21-000027 · edgar.xml · nonDerivative · entry 1 Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,397 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 15, 2020 Filed Dec 16, 2020 23:35 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | Exercise / conversionRestricted Stock Units · Derivative | 5,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001177648-20-000055 · edgar.xml · derivative · entry 3 Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Restricted stock units convert into ENTA common stock on a one-for-one basis. F4 · derivative.exercise_date: On November 18, 2016, the reporting person was granted 10,500 restricted stock units. 5,250 restricted stock units have previously vested and the remainder vested on November 18, 2020. F4 · derivative.expiration_date: On November 18, 2016, the reporting person was granted 10,500 restricted stock units. 5,250 restricted stock units have previously vested and the remainder vested on November 18, 2020. Read SEC document |
| December 15, 2020 Filed Dec 16, 2020 23:35 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | Tax withholdingCommon Stock | 1,540 | $42.52 | $65,480.80 |
DisclosureSEC source: 0001177648-20-000055 · edgar.xml · nonDerivative · entry 2 Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,944 F3 · shares: Represents the number of shares of ENTA common stock forfeited by the reporting person to cover withholding taxes due as a result of settlement of the restricted stock unit award. Read SEC document |
| December 15, 2020 Filed Dec 16, 2020 23:35 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | Exercise / conversionCommon Stock | 5,250 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001177648-20-000055 · edgar.xml · nonDerivative · entry 1 Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,484 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares of ENTA common stock subject to a restricted stock unit award granted on November 18, 2016 that vested on November 18, 2020. The settlement and issuance of the shares was subject to continued employment and occurred on December 15, 2020. F2 · price: Restricted stock units convert into ENTA common stock on a one-for-one basis. Read SEC document |
| November 20, 2020 Filed Nov 21, 2020 01:34 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | GrantStock Option (right to buy) · Derivative | 30,800 | $0.00 Strike: $43.57 | $0.00 |
DisclosureSEC source: 0001177648-20-000041 · edgar.xml · derivative · entry 2 Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,800 Underlying: Common Stock · 30,800 shares Expires 2030-11-20 F2 · derivative.exercise_date: Such option will become exercisable (subject to the optionholder's continued employment) quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over four years from the date of grant (November 20, 2020). Read SEC document |
| November 20, 2020 Filed Nov 21, 2020 01:34 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | GrantCommon Stock | 7,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001177648-20-000041 · edgar.xml · nonDerivative · entry 1 Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,234 F1 · kind: Represents a grant of restricted stock units ("RSUs") under the Enanta Pharmaceuticals, Inc. ("Enanta") 2019 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Enanta common stock. The RSUs vest in equal annual installments over four years from the date of grant (November 20, 2020). The restricted stock unit shares that vest will be issued on the first December 1 after the applicable vesting date, subject to withholding of a portion of the vested shares to satisfy tax withholding requirements. Read SEC document |
| February 12, 2020 Filed Feb 18, 2020 11:06 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | Tax withholdingCommon Stock | 1,091 | $52.76 | $57,561.16 |
DisclosureSEC source: 0001177648-20-000009 · edgar.xml · nonDerivative · entry 3 Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,634 F3 · shares: Represents the number of shares of common stock automatically forfeited by the reporting person to cover withholding taxes due as a result of settlement of the PSU and rTSRU awards. Read SEC document |
| February 12, 2020 Filed Feb 18, 2020 11:06 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | GrantCommon Stock | 2,925 | $0.00 | $0.00 |
DisclosureSEC source: 0001177648-20-000009 · edgar.xml · nonDerivative · entry 2 Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,725 F2 · shares: Represents shares of Enanta common stock issued under a relative total stockholder return unit ("rTSRU") award granted to the reporting person on March 1, 2018 that was subject to performance-vesting restrictions based on the relative total stockholder return of Enanta's common stock in relation to the total stockholder return of the component companies in the Nasdaq Biotech Index over a two-year period. The performance level was determined by the Compensation Committee of Enanta's Board of Directors and the rTSRU settled with the issuance of the shares of Enanta common stock on February 12, 2020. Read SEC document |
| February 12, 2020 Filed Feb 18, 2020 11:06 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | GrantCommon Stock | 487 | $0.00 | $0.00 |
DisclosureSEC source: 0001177648-20-000009 · edgar.xml · nonDerivative · entry 1 Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,800 F1 · shares: Represents shares of Enanta common stock issued under a performance share unit ("PSU") award granted on March 1, 2018 that vested as a result of the achievement of a research and development milestone in calendar 2019 as determined by the Compensation Committee of Enanta's Board of Directors, and then settled with the issuance of the shares of Enanta common stock on February 12, 2020. Read SEC document |
| December 16, 2019 Filed Jan 6, 2020 23:20 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | Exercise / conversionRestricted Stock Units · Derivative | 5,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001177648-20-000004 · edgar.xml · derivative · entry 3 Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,250 Underlying: Common Stock · 5,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Restricted stock units convert into ENTA common stock on a one-for-one basis. F4 · derivative.exercise_date: On November 18, 2016, the reporting person was granted 10,500 restricted stock units. 5,250 restricted stock units vested on November 18, 2019 and the remainder will vest on November 18, 2020, subject to the reporting person's continued employment. F4 · derivative.expiration_date: On November 18, 2016, the reporting person was granted 10,500 restricted stock units. 5,250 restricted stock units vested on November 18, 2019 and the remainder will vest on November 18, 2020, subject to the reporting person's continued employment. Read SEC document |
| December 16, 2019 Filed Jan 6, 2020 23:20 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | Tax withholdingCommon Stock | 2,331 | $63.88 | $148,904.28 |
DisclosureSEC source: 0001177648-20-000004 · edgar.xml · nonDerivative · entry 2 Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,313 F3 · shares: Represents the number of shares of ENTA common stock forfeited by the reporting person to cover withholding taxes due as a result of settlement of the restricted stock unit award. Read SEC document |
| December 16, 2019 Filed Jan 6, 2020 23:20 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | Exercise / conversionCommon Stock | 5,250 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001177648-20-000004 · edgar.xml · nonDerivative · entry 1 Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,644 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares of ENTA common stock subject to a restricted stock unit award granted on November 18, 2016 that vested on November 18, 2019. The settlement and issuance of the shares was subject to continued employment and occurred on December 16, 2019. F2 · price: Restricted stock units convert into ENTA common stock on a one-for-one basis. Read SEC document |
| November 18, 2019 Filed Nov 18, 2019 23:44 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $63.35 | $0.00 |
DisclosureSEC source: 0001177648-19-000036 · edgar.xml · derivative · entry 1 Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2029-11-18 F1 · derivative.exercise_date: Such option will become exercisable (subject to the optionholder's continued employment) quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over four years from the date of grant (November 18, 2019). Read SEC document |
| February 12, 2019 Filed Feb 14, 2019 02:33 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | Tax withholdingCommon Stock | 5,356 | $88.88 | $476,041.28 |
DisclosureSEC source: 0001177648-19-000015 · edgar.xml · nonDerivative · entry 3 Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,394 F3 · shares: Represents the number of shares of common stock automatically forfeited by the reporting person to cover withholding taxes due as a result of settlement of the PSU and rTSRU awards. Read SEC document |
| February 12, 2019 Filed Feb 14, 2019 02:33 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | GrantCommon Stock | 11,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001177648-19-000015 · edgar.xml · nonDerivative · entry 2 Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,750 F2 · shares: Represents shares of Enanta common stock issued under a relative total stockholder return unit ("rTSRU") award granted to the reporting person on January 4, 2017 that was subject to performance-vesting restrictions based on the relative total stockholder return of Enanta's common stock in relation to the total stockholder return of the component companies in the Nasdaq Biotech Index over a two-year period. The performance level was determined by the Compensation Committee of Enanta's Board of Directors and the rTSRU settled with the issuance of the shares of Enanta common stock on February 12, 2019. Read SEC document |
| February 12, 2019 Filed Feb 14, 2019 02:33 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | GrantCommon Stock | 4,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001177648-19-000015 · edgar.xml · nonDerivative · entry 1 Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,500 F1 · shares: Represents shares of Enanta common stock issued under a performance share unit ("PSU") award granted on January 4, 2017 that vested as a result of the achievement of a clinical development milestone in calendar 2018 as determined by the Compensation Committee of Enanta's Board of Directors, and then settled with the issuance of the shares of Enanta common stock on February 12, 2019. Read SEC document |
| November 16, 2018 Filed Nov 21, 2018 01:04 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $81.20 | $0.00 |
DisclosureSEC source: 0001177648-18-000044 · edgar.xml · derivative · entry 1 Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2028-11-16 F1 · derivative.exercise_date: Such option will become exercisable (subject to the optionholder's continued employment) quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over four years from the date of grant (November 16, 2018). Read SEC document |
| September 20, 2018 Filed Sep 21, 2018 20:18 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,955 | $0.00 Strike: $43.46 | $0.00 |
DisclosureSEC source: 0001177648-18-000035 · edgar.xml · derivative · entry 7 Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,270 Underlying: Common Stock · 2,955 shares Expires 2025-06-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: The option, representing a right to purchase a total of 90,000 shares, became or will become exercisable as follows: twenty-five percent (25%) of the shares subject to such option became exercisable on June 29, 2016 (the "Anniversary Date") and the remainder became or will become exercisable quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over three years after the Anniversary Date. Read SEC document |
| September 20, 2018 Filed Sep 21, 2018 20:18 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | SaleCommon Stock | 1,371 | $96.89 | $132,841.95 |
DisclosureSEC source: 0001177648-18-000035 · edgar.xml · nonDerivative · entry 6 Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in March 2018. F6 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $96.46 to $97.29, inclusive. Read SEC document |
| September 20, 2018 Filed Sep 21, 2018 20:18 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | SaleCommon Stock | 602 | $95.84 | $57,698.63 |
DisclosureSEC source: 0001177648-18-000035 · edgar.xml · nonDerivative · entry 5 Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,371 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in March 2018. F5 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $95.76 to $96.26, inclusive. Read SEC document |
| September 20, 2018 Filed Sep 21, 2018 20:18 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | SaleCommon Stock | 1,229 | $94.75 | $116,451.31 |
DisclosureSEC source: 0001177648-18-000035 · edgar.xml · nonDerivative · entry 4 Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,973 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in March 2018. F4 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $94.35 to $95.12, inclusive. Read SEC document |
| September 20, 2018 Filed Sep 21, 2018 20:18 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | SaleCommon Stock | 453 | $93.90 | $42,535.11 |
DisclosureSEC source: 0001177648-18-000035 · edgar.xml · nonDerivative · entry 3 Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,202 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in March 2018. F3 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $93.34 to $94.11, inclusive. Read SEC document |
| September 20, 2018 Filed Sep 21, 2018 20:18 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | SaleCommon Stock | 500 | $93.02 | $46,509.10 |
DisclosureSEC source: 0001177648-18-000035 · edgar.xml · nonDerivative · entry 2 Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,655 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in March 2018. F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $92.87 to $93.08, inclusive. Read SEC document |
| September 20, 2018 Filed Sep 21, 2018 20:18 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | Exercise / conversionCommon Stock | 2,955 | $43.46 | $128,424.30 |
DisclosureSEC source: 0001177648-18-000035 · edgar.xml · nonDerivative · entry 1 Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,155 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 20, 2018 Filed Aug 21, 2018 22:02 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,955 | $0.00 Strike: $43.46 | $0.00 |
DisclosureSEC source: 0001177648-18-000033 · edgar.xml · derivative · entry 6 Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,225 Underlying: Common Stock · 2,955 shares Expires 2025-06-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The option, representing a right to purchase a total of 90,000 shares, became or will become exercisable as follows: twenty-five percent (25%) of the shares subject to such option became exercisable on June 29, 2016 (the "Anniversary Date") and the remainder became or will become exercisable quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over three years after the Anniversary Date. Read SEC document |
| August 20, 2018 Filed Aug 21, 2018 22:02 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | SaleCommon Stock | 659 | $93.49 | $61,612.61 |
DisclosureSEC source: 0001177648-18-000033 · edgar.xml · nonDerivative · entry 5 Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 310 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in March 2018. F5 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $93.07 to $94.03, inclusive. Read SEC document |
| August 20, 2018 Filed Aug 21, 2018 22:02 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | SaleCommon Stock | 2,224 | $92.68 | $206,129.88 |
DisclosureSEC source: 0001177648-18-000033 · edgar.xml · nonDerivative · entry 4 Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 969 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in March 2018. F4 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $92.00 to $92.95, inclusive. Read SEC document |
| August 20, 2018 Filed Aug 21, 2018 22:02 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | SaleCommon Stock | 700 | $91.49 | $64,042.02 |
DisclosureSEC source: 0001177648-18-000033 · edgar.xml · nonDerivative · entry 3 Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,193 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in March 2018. F3 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $91.35 to $91.67, inclusive. Read SEC document |
| August 20, 2018 Filed Aug 21, 2018 22:02 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | SaleCommon Stock | 572 | $90.58 | $51,811.65 |
DisclosureSEC source: 0001177648-18-000033 · edgar.xml · nonDerivative · entry 2 Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,893 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in March 2018. F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $90.30 to $90.74, inclusive. Read SEC document |
| August 20, 2018 Filed Aug 21, 2018 22:02 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | Exercise / conversionCommon Stock | 2,955 | $43.46 | $128,424.30 |
DisclosureSEC source: 0001177648-18-000033 · edgar.xml · nonDerivative · entry 1 Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,465 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 18, 2018 Filed Jul 19, 2018 20:35 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,955 | $0.00 Strike: $43.46 | $0.00 |
DisclosureSEC source: 0001177648-18-000031 · edgar.xml · derivative · entry 6 Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,180 Underlying: Common Stock · 2,955 shares Expires 2025-06-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The option, representing a right to purchase a total of 90,000 shares, became or will become exercisable as follows: twenty-five percent (25%) of the shares subject to such option became exercisable on June 29, 2016 (the "Anniversary Date") and the remainder became or will become exercisable quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over three years after the Anniversary Date. Read SEC document |
| July 18, 2018 Filed Jul 19, 2018 20:35 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | SaleCommon Stock | 904 | $126.40 | $114,261.35 |
DisclosureSEC source: 0001177648-18-000031 · edgar.xml · nonDerivative · entry 5 Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,510 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in March 2018. F5 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $126.12 to $126.90, inclusive. Read SEC document |
| July 18, 2018 Filed Jul 19, 2018 20:35 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | SaleCommon Stock | 1,621 | $125.60 | $203,602.30 |
DisclosureSEC source: 0001177648-18-000031 · edgar.xml · nonDerivative · entry 4 Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,414 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in March 2018. F4 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $125.09 to $126.07, inclusive. Read SEC document |
| July 18, 2018 Filed Jul 19, 2018 20:35 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | SaleCommon Stock | 445 | $124.20 | $55,269.36 |
DisclosureSEC source: 0001177648-18-000031 · edgar.xml · nonDerivative · entry 3 Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,035 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in March 2018. F3 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $123.95 to $124.48, inclusive. Read SEC document |
| July 18, 2018 Filed Jul 19, 2018 20:35 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | SaleCommon Stock | 2,075 | $123.72 | $256,709.66 |
DisclosureSEC source: 0001177648-18-000031 · edgar.xml · nonDerivative · entry 2 Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,480 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in March 2018. F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $122.925 to $123.87, inclusive. Read SEC document |
| July 18, 2018 Filed Jul 19, 2018 20:35 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | Exercise / conversionCommon Stock | 2,955 | $43.46 | $128,424.30 |
DisclosureSEC source: 0001177648-18-000031 · edgar.xml · nonDerivative · entry 1 Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,555 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 18, 2018 Filed Sep 21, 2018 20:15 UTC Amendment | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | SaleCommon Stock | 904 | $126.40 | $114,261.35 |
DisclosureSEC source: 0001177648-18-000034 · edgar.xml · nonDerivative · entry 4 Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,400 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in March 2018. F5 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $126.12 to $126.90, inclusive. F6 · balance_after: The Form 4 filed by the reporting person on July 19, 2018 is being amended to correct: (i) a scrivener's error with regard to the number of shares reported as disposed in column 4 and (ii) the corresponding amount of securities beneficially owned following reported transactions in column 5. The subsequent Form 4 filed by the reporting person on August 21, 2018 does not reflect the correction made in this amendment to the amount of securities beneficially owned following reported transactions. Read SEC document |
| July 18, 2018 Filed Sep 21, 2018 20:15 UTC Amendment | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | SaleCommon Stock | 1,621 | $125.60 | $203,602.30 |
DisclosureSEC source: 0001177648-18-000034 · edgar.xml · nonDerivative · entry 3 Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,304 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in March 2018. F4 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $125.09 to $126.07, inclusive. F6 · balance_after: The Form 4 filed by the reporting person on July 19, 2018 is being amended to correct: (i) a scrivener's error with regard to the number of shares reported as disposed in column 4 and (ii) the corresponding amount of securities beneficially owned following reported transactions in column 5. The subsequent Form 4 filed by the reporting person on August 21, 2018 does not reflect the correction made in this amendment to the amount of securities beneficially owned following reported transactions. Read SEC document |
| July 18, 2018 Filed Sep 21, 2018 20:15 UTC Amendment | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | SaleCommon Stock | 445 | $124.20 | $55,269.36 |
DisclosureSEC source: 0001177648-18-000034 · edgar.xml · nonDerivative · entry 2 Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,925 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in March 2018. F3 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $123.95 to $124.48, inclusive. F6 · balance_after: The Form 4 filed by the reporting person on July 19, 2018 is being amended to correct: (i) a scrivener's error with regard to the number of shares reported as disposed in column 4 and (ii) the corresponding amount of securities beneficially owned following reported transactions in column 5. The subsequent Form 4 filed by the reporting person on August 21, 2018 does not reflect the correction made in this amendment to the amount of securities beneficially owned following reported transactions. Read SEC document |
| July 18, 2018 Filed Sep 21, 2018 20:15 UTC Amendment | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | SaleCommon Stock | 1,185 | $123.72 | $146,602.87 |
DisclosureSEC source: 0001177648-18-000034 · edgar.xml · nonDerivative · entry 1 Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,370 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in March 2018. F6 · shares: The Form 4 filed by the reporting person on July 19, 2018 is being amended to correct: (i) a scrivener's error with regard to the number of shares reported as disposed in column 4 and (ii) the corresponding amount of securities beneficially owned following reported transactions in column 5. The subsequent Form 4 filed by the reporting person on August 21, 2018 does not reflect the correction made in this amendment to the amount of securities beneficially owned following reported transactions. F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $122.925 to $123.87, inclusive. F6 · balance_after: The Form 4 filed by the reporting person on July 19, 2018 is being amended to correct: (i) a scrivener's error with regard to the number of shares reported as disposed in column 4 and (ii) the corresponding amount of securities beneficially owned following reported transactions in column 5. The subsequent Form 4 filed by the reporting person on August 21, 2018 does not reflect the correction made in this amendment to the amount of securities beneficially owned following reported transactions. Read SEC document |
| June 18, 2018 Filed Jun 19, 2018 21:13 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,955 | $0.00 Strike: $43.46 | $0.00 |
DisclosureSEC source: 0001177648-18-000028 · edgar.xml · derivative · entry 5 Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,135 Underlying: Common Stock · 2,955 shares Expires 2025-06-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option, representing a right to purchase a total of 90,000 shares, became or will become exercisable as follows: twenty-five percent (25%) of the shares subject to such option became exercisable on June 29, 2016 (the "Anniversary Date") and the remainder became or will become exercisable quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over three years after the Anniversary Date. Read SEC document |
| June 18, 2018 Filed Jun 19, 2018 21:13 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | SaleCommon Stock | 658 | $115.89 | $76,253.91 |
DisclosureSEC source: 0001177648-18-000028 · edgar.xml · nonDerivative · entry 4 Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,600 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in March 2018. F4 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $115.65 to $116.08, inclusive. Read SEC document |
| June 18, 2018 Filed Jun 19, 2018 21:13 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | SaleCommon Stock | 2,229 | $115.09 | $256,542.07 |
DisclosureSEC source: 0001177648-18-000028 · edgar.xml · nonDerivative · entry 3 Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,258 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in March 2018. F3 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $114.55 to $115.51, inclusive. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.